Meeting
2017 ASCO Annual Meeting
A phase Ib study combining irinotecan with AZD1775, a selective WEE 1 kinase inhibitor, in RAS/RAF mutated metastatic colorectal cancer patients who progressed on first line therapy.
Authors
Deirdre Jill Cohen
Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY
Deirdre Jill Cohen , Elda Grabocka , Dafna Bar-Sagi , Robert Godin , Lawrence P. Leichman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT02906059
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS3627)
DOI
10.1200/JCO.2017.35.15_suppl.TPS3627
Abstract #
TPS3627
Poster Bd #
245b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Prognostic role of TP53 variants in the phase III study of FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (ERMES study).
First Author: Nicola Normanno
Poster
2022 ASCO Annual Meeting
The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC).
First Author: Jenny F. Seligmann
Poster
2020 Gastrointestinal Cancers Symposium
Clinical utility of comprehensive circulating tumor DNA (ctDNA) testing compared to standard-of-care (SoC) tissue testing in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts).
First Author: Manuel Benavides
Poster
2020 Gastrointestinal Cancers Symposium
Treatment of metastatic colorectal cancer (mCRC) according to age.
First Author: Laura Ortega